-
A second NS3/4A protease inhibitor has been approved by the FDA for the treatment of chronic hepatitis C (HCV) genotype 1, joining the recently approved boceprevir (Victrelis). Telaprevir is marketed by Vertex Pharmaceuticals as Incivek.
-
-
Proton pump inhibitor use in clopidogrel-treated post-percutaneous coronary intervention patients was not associated with an increased risk of all-cause death, nonfatal myocardial infarction, repeat revascularization, or major adverse cardiovascular events.
-
-
Cerebrovascular events (CVE), including stroke and transient ischemic attack (TIA), are recognized complications of percutaneous coronary intervention (PCI).
-
Hypertension is usually asymptomatic, so adherence to drug therapy is an issue, especially if the drugs used cause symptoms.
-
Frontal lobe dysfunction may predispose people to have psychogenic nonepileptic seizures; this dysfunction can be measured by analyzing a brief period of the awake EEG.
-
-
This observational study noted that critically ill patients provided with clinical psychological support during their ICU stay had less anxiety, depression, and post-traumatic stress disorder at one year post-discharge compared to historical controls.
-
In a cohort of mechanically ventilated patients admitted with a variety of acute diagnoses, those diagnosed with COPD (but not in exacerbation) had higher ICU mortality but no difference in risk for ventilator-associated pneumonia as compared to patients without the diagnosis of COPD.
